Abstract YO14
Case summary
Urachal cancer is a rare neoplasm which represents approximately 0.5-2% of all bladder cancer.
A 52 year old Filipino male presented with painless hematuria. Physical examination was unremarkable. KUB ultrasound showed a bladder mass so Cystoscopy–TUR was done. Histopathology revealed adenocarcinoma with involvement of muscularis propria. He was advised surgery but did not consent. Contrast-enhanced abdominal computed tomography (CT) showed a well-defined, slightly wall enhancing, midline infraumbilical complex soft tissue mass measuring 3.6x4.0x5.1cm in the anterosuperior aspect of the urinary bladder extending to the urachus with no communication to the umbilicus. Cystoscopy, Partial Cystectomy with Umbilectomy was done. Intra-operative findings: bladder mass at the dome approximately 2-3cm in size, necrotic tissue with band of tissue directly connected to the umbilicus. Histopathology was urachal adenocarcinoma which extends to the urinary bladder muscularis propria and perivesical tissue. He was advised close follow-up.
After one year, he started to experience difficulty initiating urine. Repeat CT scan showed: urinary bladder with an intraluminal enhancing nodule in the superoanterior wall measuring 1.5x1.7cm, irregular anterior urinary bladder wall thickening measuring 7.3x1.5cm is also noted, small anterior perivesical nodes are noted measuring 0.7x1.2 cm. Cysto-TURP of Bladder Tumor, Exploratory Laparotomy, Adhesiolysis, was done. Intra-operative findings were: smooth urethral mucosa without stenosis or stricture; pedunculated broad-based, friable, pink fleshy mass seen at the posterolateral bladder wall, measuring 5-8 cm in greatest diameter; flat erythematous lesion measuring 2cm noted at bladder dome; muiltiple nodularities along peritoneum with some attached to ileal loops. Specimen’s pathology reported adenocarcinoma and peritoneal nodularities were metastatic adenocarcinoma; morphological features favored the diagnosis of urachal adenocarcinoma. CT scan of the Chest showed innumerable varisized non-calcified parenchymal, fissural, and subpleural nodules scattered in both lungs which were worrisome for metastasis. The patient has received systemic chemotherapy with Cisplatin and Fluorouracil.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract